LILLY TO DIVEST MEDICAL DEVICE/DIAGNOSTIC BUSINESSES TO FOCUS ON DRUGS; OTHER RESTRUCTURING TO RESULT IN $1.2 BIL. CHARGE AND LOSS IN 4TH QUARTER
This article was originally published in The Gray Sheet
Executive SummaryLilly plans to shed its medical device/diagnostics businesses to focus on pharmaceuticals, the firm announced Jan. 18. The widely anticipated decision is the result of a "strategic review" initiated by Lilly execs in June 1993.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.